Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Curr Hematol Malig Rep. 2006 Mar;1(1):34-8. doi: 10.1007/s11899-006-0015-6.
Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy.
骨髓增生异常综合征（MDS）是一种异质性骨髓疾病，主要影响老年人，而骨髓移植作为唯一的治愈性疗法，对他们来说很少是一种选择。新的治疗方法，或历史治疗方法的新应用，都迫切需要。三氧化二砷（ATO）通过促凋亡、抗增殖和抗血管生成机制发挥作用，已成功用于治疗多种血液系统恶性肿瘤，包括 MDS。作为单一疗法或与其他药物联合使用，它可以使 22%至 26%的患者获得血液学改善，且副作用可耐受。特别是那些细胞表达 EVI1 突变的 MDS 患者可能从这种治疗中受益。
